Kornimate/medical-research-clean huggingface dataset:
study evaluating the efficacy of allogeneic transplant conditioning with adaptive dose busulfan intravenous (busilvex®) in patients at high risk of carrying blood diseases

Conditions: Hematological Diseases

Summary: determine the efficiency of a myéloablative conditioning associating fludarabine, thymoglobuline, and intravenous busulfan with adapted dose, according to a pharmacokinetics realized in the first day of administration (or j-6 of the conditioning) of the busulfan, in preparation for a allogenic transplant family or not family compatible hla.


Eligibility criteria:
inclusion criteria : * informed consent signed, * patient affiliated to a social security system or benefiting from such a system, * related hla identical donor or unrelated hla identical donor : all patients aged \> 55 years with hematological malignancy and deemed eligible for an allogeneic transplant from a geno-identical donor and pheno-identical 10/10 - the basic pathology should be considered "chemo-sensitive" complete or partial remission (cr, pr) or stable disease exclusion criteria : * pregnant or lactating woman or without contraception (for child bearing potential women) * patient deprived of liberty or under supervision of a guardian * impossibility to undergo medical examinations of the study for geographical, social or psychological reasons * usual contra-indications for allogenic transplant * aged \< 55 years * history of allogenic transplant * concomitant neoplastic disease * evolutive psychiatric disease * hiv seropositivity or c hepatitis under treatment * women of childbearing age or man, in the absence of effective contraception during treatment and up to 12 months after treatment discontinuation
apolipoprotein polymorphisms and risk of coronary heart disease

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Arteriosclerosis; Coronary Disease

Summary: to determine the relative risk in a defined population of angiographically demonstrated coronary artery disease due to genetic polymorphisms at the four apolipoprotein genomic regions.

background: numerous epidemiological studies have shown that the risk of coronary heart disease is strongly influenced by plasma lipid levels, especially hdl and ldl cholesterol, and their specific apolipoprotein constituents. genetic studies have established significant heritability of these lipid components, and have also identified relatively rare major genes that result in extreme lipid values and increased risk of coronary heart disease. geneticists have identified a number of segregating polymorphisms at the four major apolipoprotein genomic regions, using a combination of protein and dna assays. however, in 1988 when the study was initiated, the relationship between these polymorphisms and risk of coronary heart disease had not yet been properly defined. design narrative: the study had a case-control design. cases were consecutively selected from the pool of eligible latter day saints hospital patients referred for coronary angiogram. eligibility criteria included residing in the wasatch county or southern idaho counties, being healthy at the time of angiogram and having greater than 60 percent occlusion. approximately 80-100 controls were retrospectively selected from the clinic records of the past four years. fasting lipid profiles were defined for cases and controls in terms of total cholesterol, total triglycerides, hdl levels, ldl levels, vldl levels, density gradient distribution of hdl-ldl subfractions, and levels of apo a-1, apo b, and apo e. the distribution of genetic polymorphisms at the four major apolipoprotein genomic regions was determined by typing all cases and controls for isoforms of apo e and apo aiv and a wide variety of dna polymorphisms. approximately 800 first degree relatives of cases and controls were also typed for dna polymorphisms. data were collected on risk factors including smoking, alcohol use, obesity, physical activity, and diet. clinical data included medical and family history of cardiovascular disease and medication status. multivariate statistical analysis was used to define the relative risk of coronary disease associated with segregating polymorphisms, and dna haplotypes at these loci in conjunction with lipid profiles and risk factors. analyses were also conducted on the extent to which the genetic segregation at these apolipoprotein genomic regions influenced the distribution of lipid profiles and whether the distribution of risk factors was influenced by the interaction of environmental risk factors such as smoking and genotypes at these regions.

Eligibility criteria:
no eligibility criteria
armeosenso - reward

Conditions: Stroke

Summary: this study investigates the use of motivating/rewarding features in a computer based arm rehabilitation program. half of the subjects will take part, besides receiving standard therapy, in a computer based program delivering a game like scenario with visual effects and monetary rewards in case of successful level completion, while the other half will take part in a similar program without visual effects or the possibility to earn money.

rewards not only increase motivation to train, but have also been shown to influence motor skill learning via activation of dopaminergic brain structures. in goal oriented tasks, receiving information about goal achievement has a rewarding value, which is further increased if performance has monetary consequences. computer games often strengthen this kind of information by presenting explosions and other salient stimuli when a goal is achieved (e.g. a target has been reached). the current study investigates the outcome of an arm rehabilitation program, based on such a computer game delivered in two versions. stroke patients are asked to use their impaired arms to perform goal oriented movements. movements are translated into movements of a virtual arm on a computer screen. goals are "meteors", threatening to destroy a planet on which they fall, if not caught by the virtual arm. one version of the computer game delivers state of the art graphics including a number of visual effects and, if the planet was protected successfully, information about a monetary reward, whereas the other version of the program delivers schematic graphic objects only. training time and intensity are kept constant and outcome measures, including standard clinical motor assessments, are compared between the groups.

Eligibility criteria:
inclusion criteria: * stroke survivor (max. 100 days post-stroke) * upper extremity motor deficits * patient can lift the paretic arm against gravity * patient can move the hand at least 20x20 cm in a horizontal plane * patient is able and willing to participate * patient has signed informed consent exclusion criteria: * severe aphasia (impairing verbal instructions) * severe dementia (impairing the capability to understand instructions) * severe depression (impairing motivation to train) * relevant (in the judgement of the investigator) impairment of visual perception, (impairing perception of goals and feedback on the computer screen)

Keywords: rehabilitation virtual reality stroke upper extremity arm feedback reward
effect of high flow nasal cannula vs. standard care on respiratory stability in pediatric procedural sedation

Conditions: Respiratory Insufficiency

Summary: procedural sedation is an established and safe intervention and is widely used in diagnostic and therapeutic procedures for pediatric patients. nonetheless, problems of the respiratory system such as upper airway obstruction, hypoventilation and apnea are frequent adverse events. we postulate that respiratory instability is less frequent in patients high flow nasal cannula vs. standard care on respiratory stability, i.e. low flow nasal cannula, in pediatric procedural sedation. the purpose of this pilot study is to estimate the effect of hfnc (high flow nasal cannula) on the respiratory instability in children undergoing upper gastrointestinal endoscopy under pediatric procedural sedation (pps).


Eligibility criteria:
inclusion criteria: 1. age 6 years - 18 years 2. undergoing pediatric non-emergency upper gastrointestinal endoscopy under sedation 3. informed consent/assent for enrollment by parents/legal guardians/patient exclusion criteria: 1. congenital or acquired malformations involving the airways 2. patients with the history of spontaneous pneumothorax or connectives tissue diseases (marfan syndrome, ehlers-danlos-syndrome) 3. patients with a history of traumatic/iatrogenic air leak within the last 3 months before enrollment

Keywords: apnea children hypercarbia procedural sedation hfnc
effect of high intensity laser in patellofemoral pain syndrome

Conditions: Physical Therapy; Orthopedic Disorder

Summary: the aim of this study is to investigate the effectiveness of high-intensity laser therapy on pain and lower extremity function in the treatment of patellofemoral pain syndrome.

participants between the ages of 25-45 who were diagnosed with unilateral patellofemoral pain syndrome by the doctor will be included in the study. also positive clarke's test and patellar compression tests will be determined as inclusion criteria. the 45 participants will be randomly divided into three groups. both groups will receive 2 weeks (5 sessions per week) of therapy. first group patients underwent high intensity laser therapy (hilt) and exercises. second group patients will be treated by transcutaneous electrical nerve stimulation(tens), ultrasound (us) and exercise for 10 sessions. also in the third group patients will be treated with ultrasound (us),interferential current stimulation and exercise. all groups receive the same exercise exercise protocol including muscle strengthening and flexibility training for 12 weeks. the outcomes will be pain intensity measured by visual analog scale (vas) , knee flexion range of motion (from), timed up and go test (tug),muscle strength measured with handheld dynamometer, pressure pain threshold with an algometry and functionality of knee measured by the lower extremity functional scale and kujala patellofemoral questionnaire. statistical analyzes will be performed to compare amounts at baseline, immediately after treatment, and after 12 weeks.

Eligibility criteria:
inclusion criteria: * unilateral patellofemoral pain syndrome diagnosed by a doctor * 25-45 years old * pain from prolonged sitting, climbing and descending stairs, running,knee bend more than 3 months * positive patellar compression and clarke's tests. exclusion criteria: * previous knee pain, trauma, surgery and other joint diseases, * knee ligament, bursa, meniscus and synovial fold injury or dysfunction * osteoarthritis in the knee joint, * neurological problems that may affect walking * pregnancy * no chronic disease * malignancy, * presence of infection

Keywords: patellofemoral pain high intensity laser therapy
shockwave phonophoresis on calcaneal spur patients

Conditions: Calcaneal Spur

Summary: the low energy shockwave has a significant effect on the permeability of tissue. consequently, it might be used to deliver a substance such as acetic acid. accordingly, shockwave might help to improve the outcomes with calcaneal spur patients. therefore, the present study might help in the treatment of calcaneal spur patients and also might improve the quality of life in a fast and efficient way.


Eligibility criteria:
inclusion criteria: * heel pain with a calcaneal spur. * calcaneal spur in a lateral calcaneal x-ray. * patient's age ranged from 30 to 65 years. * patients with a calcaneal spur. * patients with intact sensory perception. * at least 6 weeks from last corticosteroid injection; 4 weeks from the last local anaesthetic injection, iontophoresis, ultrasound, and electrotherapy exclusion criteria: * history of fracture or surgery of the heel or ankle. * presence of inflammatory joint disease. * marked osteoporotic patient. * presence of ankylosing spondylitis or other inflammatory joint diseases. * heart pacemaker use. * patient on anticoagulant and coagulation disease. * skin wound or ulcers.
making activity time for cognitive health

Conditions: Breast Cancer; Cancer-related Problem/Condition; Cognitive Impairment; Physical Activity

Summary: approximately 75% of cancer survivors experience some degree of cognitive deficit throughout their cancer experience, with upwards of one third of breast cancer survivors reporting impairments up to a decade after treatment. chemotherapy and adjuvant therapy to remove cancerous tissue can result in deficits in attention, speed of processing, memory, and quality of life. physical activity has been associated with a number of health benefits for breast cancer survivors including improvements in cognitive function. the investigators recently reported on the beneficial effects of acute exercise, or single sessions of physical activity, on processing speed and spatial working memory in breast cancer survivors, suggesting that acute bouts of physical activity may mitigate select domains of crci. specifically, survivors in this study demonstrated faster processing speed, and trended towards faster and more accurate spatial working memory, after thirty minutes of moderate-intensity walking compared to seated rest. but half an hour of walking may be challenging to certain subgroups of survivors, particularly those who are deconditioned or with significant barriers to longer walks. with a renewed focus on un-bouted physical activity and avoiding inactivity during survivorship, it is important to better understand the dose or volume of exercise responsible for providing breast cancer survivors with the greatest cognitive benefits. the investigators examined the effects of varying durations of exercise (e.g., 10, 20 and 30 minutes) on cognitive function in breast cancer survivors to identify the optimal length of acute exercise. findings from this study will inform new guidelines for acute exercise after cancer.


Eligibility criteria:
inclusion criteria: * women over the age of 18 * diagnosis of breast cancer * no longer undergoing treatment * fluent in english * no history of dementia or organic brain syndrome * not currently pregnant * able to walk unassisted * no health reasons that would prevent ability to exercise * not currently enrolled in another exercise research study * reported trouble with memory/concentration * physician's consent exclusion criteria: * male * no diagnosis of breast cancer * under 18 years of age * currently undergoing treatment for breast cancer * inability to communicate in english * history of dementia or organic brain syndrome * pregnant * unable to walk unassisted * other health reasons that may prevent ability to exercise * enrolled in another exercise research study * no reported trouble with memory or concentration * non-consent of physician
misoprostol prior to office hysteroscopy in patients with no risk factors for experiencing unacceptable pain

Conditions: Pain

Summary: the aim of this study is to assess whether vaginal misoprostol reduces pain during office hysteroscopy in parous patients with no risk factors for experiencing severe or unacceptable pain.

cervical ripening with misoprostol to minimize the pain experienced during office hysteroscopy has been proposed by several authors. the use of misoprostol is usually associated with undesired side effects and therefore any beneficial effect of misoprostol on reducing pain should be weighed against its undesired side effects (nausea, vomiting, diarrhea, fever, shivering, pain) and coasts. till now , no studies have yet determined whether misoprostol should be used routinely or for the subgroup of patients at higher risk for cervical stenosis. the aim of this study is to assess whether vaginal misoprostol reduces pain during office hysteroscopy in parous patients with no risk factors for experiencing severe or unacceptable pain.

Eligibility criteria:
inclusion criteria: * patients with at least one vaginal delivery who have an indication for office hysteroscopy. exclusion criteria: * nulliparous patients, menopausal patients and patients with cervical pathology, and previous history of caesarean section or cervical surgery

Keywords: misoprostol office hysteroscopy pain
study on dynamic environmental exposome of icu and the establishment of microbial transmission model between environment and host

Conditions: Hospital Acquired Infection; Ventilator-associated Pneumonia

Summary: hai (hospital-acquired infection) is very common in icu，and lack of understanding of environmental exposure omics and environment-host microbial interactions restricts the prevention and control of hai. in this project, the investigators try to analyze the spatial and temporal distribution characteristics and evolution of microorganisms and their functions in the icu environment through metagenome.

this observational study aims to analyze the spatial and temporal distribution characteristics and evolution of microorganisms and their functions in the icu environment. the investigators will conduct weekly air microbiome sampling and microbiome sampling at 5 high-frequency contact points in different types of icu units in three hospitals for one consecutive year, and collect dynamic pharyngeal swabs from icu ward health care workers and dynamic clinical specimens (endotracheal aspiration, and bronchoalveolar lavage fluid) from patients with ventilator-associated pneumonia in icu ward. with dna high-throughput sequencing technology, the investigators will analyze the spatial and temporal distribution characteristics and evolution of microorganisms and their functions in the icu environment, and provide support for hai prevention.

Eligibility criteria:
inclusion criteria: * with mechanical ventilation * age ≥18 years * anticipated icu stay for more than 2 days * with two or more of the following ventilator-associated pneumonia (vap) risk factors * vap risk factors: age ≥ 60 years old; patients with chronic lung disease; long-term bedridden; unconsciousness; sputum is not easily coughed up; antibiotics have been used before mechanical ventilation; long-term use of h receptor blockers and proton pump inhibitors. exclusion criteria: * patients who have not signed the informed consent * pregnant * systemic diseases and recent use of related drugs * history of infectious diseases, such as tuberculosis or ppd positive * history of hypertension and poor blood pressure control (sbp / dbp \> = 140mmhg) * with severe mental illness * long term use of traditional chinese medicine, probiotics, gastric mucosal protective agents, proton pump inhibitors, chemotherapy or immunosuppressive drugs, etc.

Keywords: environment exposure microbial colonization microbiome
a phase 1 trial of opb-111077 in combination with bendamustine and rituximab in patients with r/r dlbcl

Conditions: Relapsed or Refractory Diffuse Large B-cell Lymphoma

Summary: to investigate the tolerability and safety of opb-111077 in combination with bendamustine and rituximab in patients with r/r dlbcl.


Eligibility criteria:
inclusion criteria: * patients with a definite diagnosis of diffuse large b-cell lymphoma(dlbcl) * patients who have received at least initial standard treatment * patients with measurable lesions (based on international working group \[iwg\] 2014 criteria) * patients with an eastern cooperative oncology group (ecog) performance status (ps) score of 0 or 1 \ * patients who are pathologically diagnosed as cd20 positive lymphoma * patients who have a history of being treated with 1 to 5 regimens of previous chemotherapy for the underlying disease exclusion criteria: * patients who are candidates for autologous or allogeneic hematopoietic stem cell transplantation * patients who were refractory to initial standard treatment * patients who have a history of bendamustine administration and are intolerant to bendamustine * patients with central nervous system (cns) involvement of lymphoma or with a history of cns involvement of lymphoma * patients diagnosed with dlbcl transformed from low-grade b-cell non-hodgkin's lymphoma (nhl) \ - patients who have a history of rituximab administration and are intolerant to rituximab
study of neuroaid in enhancing recovery after stroke

Conditions: Stroke; Cerebral Infarction

Summary: tiers is a phase ii to generate detailed preliminary data on the efficacy of neuroaid in post-stroke recovery, and to assess the utility of the rehabilitation outcome measure instruments used.


Eligibility criteria:
inclusion criteria: * subject had cerebral infarction confirmed by computed tomography (ct scan or magnetic resonance imaging (mri) imaging * presents within 1 month after stroke onset * presents with motor power of from grade 1 - 4/5 in at least one limb * has a pre-stroke modified rankin score ≤ 1. * age between 21 and 80 years old * female subjects are eligible to participate in the trial if they are of non childbearing potential (hysterectomy or post-menopausal) * subject or legally acceptable representative is willing and able to provide written informed consent * subject and carer are willing and able to comply with investigational drug administration schedule. exclusion criteria: * subject has received thrombolysis * subject has evidence of intra-cerebral hemorrhage on brain ct scan or mri * subject has definite indication for full-dose or long-term anticoagulation therapy * subject has other significant non-ischemic brain lesion which could affect function disability * subject has co-existing systemic diseases: terminal cancer, renal failure (creatinine \>200 μmol/l, if known), cirrhosis, severe dementia or psychosis * subject has a history of previous stroke/s * subject has participated in another clinical trial within the last three months * subject has aphasia or any other cognitive disabilities which prevent cooperation with study instructions * subject has dense hemiplegia (grade 0 motor power) * subject has haemoglobin level of \<10mg/dl on admission * subject has a history of craniotomy or seizures

Keywords: stroke cerebral infarct rehabilitation double blind randomized placebo controlled traditional chinese medicine neuroaid
innfocus microshunt versus trabeculectomy study

Conditions: Primary Open Angle Glaucoma

Summary: assess the safety and effectiveness of the innfocus microshunt when used to lower intraocular pressure (iop) in subjects with primary open angle glaucoma where the iop is not controlled when using maximum tolerated glaucoma medications.

this clinical trial is a prospective, randomized, controlled, multicenter, study. after informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity. clinical follow up will be scheduled over the course of the 24 month study, and examinations will be repeated to monitor eye health. at the 1 and 2 year follow up, diurnal (iop taken in the morning, mid-day, and afternoon in the same day) iop evaluation will be done. annual follow up will occur up to 2 years. the primary effectiveness endpoint is 20% or greater reduction in iop from pre-op medicated iop at 12 months.

Eligibility criteria:
inclusion criteria: - poag on maximum tolerated glaucoma meds - medicated ≥15mmhg and ≤40mmhg - exclusion criteria: - previous conjunctival incisional ophthalmic surgery - anticipated need for additional ocular surgery during the study - secondary glaucoma - any condition that prevents the device implantation or trabeculectomy in the superior region of the study eye

Keywords: poag